2022/07/08
´ºÓêÖ±²¥app School of Medicine
´ºÓêÖ±²¥app Hospital
Associate Professor Hideaki Ohara, Senior Lecturer Kentaro Matsubara, and their colleagues from the Department of Surgery (General and Gastroenterological) at the ´ºÓêÖ±²¥app School of Medicine received approval from the Health Sciences Council on June 11, 2020, for their "Exploratory Clinical Trial of Adipose-Derived Stem Cell-Like Platelet-Like Cells (ASCL-PLCs) for Intractable Skin Ulcers," confirming that the plan for providing Class I regenerative medicine complies with the standards for providing regenerative medicine (see press release dated June 11, 2020). Recently, the first patient was dosed with ASCL-PLCs, and it was determined that there were no safety issues, allowing for the enrollment of subsequent patients to begin. ASCL-PLCs are a seed technology originating from ´ºÓêÖ±²¥app, created from mesenchymal stem cells found in subcutaneous adipose tissue. This developmental product has been supported by the AMED Bridge Program (Seeds B), with Project Associate Professor Yumiko Matsubara of the Clinical and Translational Research Center as the principal investigator and Project Assistant Professor Yukako Uruga and others as research and development collaborators.
Please see below for the full press release.